Ebola outbreak eases as world's largest treatment centre dismantled in Liberia
The world's largest Ebola unit, the ELWA-3 treatment centre in Liberia, is being dismantled in response to a drastic retreat of the epidemic.
The centre opened in the capital Monrovia in August with 120 beds and was immediately overwhelmed, with staff forced to turn patients away at its gates, despite more than doubling its capacity.
Five months later to the day, it registered no patients at all for the first time, and staff this week marked the reduction by burning the first tent put up at the clinic.
"The number of cases has decreased significantly - we are down to five confirmed cases in Liberia," said Duncan Bell, the field coordinator in Liberia for Medecins san Frontieres (MSF).
"In line with this development we think it was appropriate to reduce the treatment centre.
Mr Bell stressed that MSF was not closing ELWA-3, "just reducing the capacity"."Today we have 60 beds and at the end of February we hope to go down to 30 beds."
"We still have the capacity to scale up to 120 beds within 24 hours if the need arises," he said.
The worst outbreak of the virus in history has seen Liberia and its neighbours Guinea and Sierra Leone register almost 9,000 deaths in a year.
MSF said in its latest crisis update on Monday it was treating just two patients in ELWA-3.
Those were among just over 50 patients at MSF's eight Ebola units across Guinea, Liberia and Sierra Leone.
The charity's busiest Ebola management centre is currently at the Prince of Wales centre in Freetown, with 30 patients as of January 24.
Huge progress made to stop the spread
Soon after it opened, staff at ELWA-3 were struggling to screen new arrivals, care for admitted patients or safely remove dead bodies and transport them to the crematorium.
By the end of the year the centre had taken in 1,826 patients, 1,225 of whom tested positive for Ebola and 498 of whom survived.
But Liberia and its neighbours Sierra Leone and Guinea have reported huge progress on stemming the spread of Ebola since the summer, when the joint tally was several hundred new infections a week.
Liberian commerce minister Axel Addy told reporters in Geneva on Monday that 12 of Liberia's 15 counties had reported no new cases.
He said the crisis had cost Liberia $US93 million in lost revenue, with the key mining sector coming "to a grinding halt".
Children return to school
Children trickled back to school last week in Guinea, where the Ebola epidemic broke out in December 2013 and teaching is due to resume in neighbouring Liberia next week.
Classrooms in both countries have been provided with health kits containing chlorine, thermometers and soap, while teams will monitor students to detect possible infections.
Mali, which along with Senegal and Nigeria had a minor Ebola scare, was able last week to declare itself Ebola-free after 42 days without any new cases.
Senegal and Nigeria had previously already done so.
"This decline is an opportunity to focus efforts on addressing the serious weaknesses that remain in the response," said Brice de la Vingne, MSF director of operations.
"We are on the right track, but reaching zero cases will be difficult unless significant improvements are made in alerting new cases and tracing those who have been in contact with them."
He warned that just a single new case could be enough "to reignite an outbreak".
"Until everyone who has come into contact with Ebola has been identified, we cannot rest easy," he said.
The African Union plans to launch an Ebola fund and disease control centre, officials in Ethiopian capital Addis Ababa said on Wednesday, as aid agency Oxfam warned leaders needed to keep their promises to boost healthcare systems on the continent.
Oxfam called for a "massive post-Ebola Marshall Plan", referring to the United States aid package to rebuild Europe after World War II.
Vaccine trials look promising
Meanwhile, preliminary results from a clinical trial on an experimental Ebola vaccine developed by GlaxoSmithKline and the US National Institutes of Health suggested it was safe for use, according to researchers.
The vaccine trial, at Oxford University and with findings published in the New England Journal of Medicine, also generated an immune response to Ebola.
"The vaccine was well-tolerated. Its safety profile is pretty much as we had hoped," trial leader Adrian Hill said.
"People typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish.
"It's very similar to what has been seen in previous studies with this general type of vaccine."
The results were based on 60 healthy volunteers who were vaccinated between September and November.
The vaccine does not contain infectious Ebola virus, so it cannot cause a person who is vaccinated to get sick from Ebola.
There is no vaccine to guard against Ebola on the world market, and no drug approved to treat it, even though the virus first emerged in the 1970s.
GlaxoSmithKline has shipped thousands of doses to Liberia, where a randomised trial of up to 27,000 people, including health care workers, is expected to begin soon.
0 comments:
Post a Comment